{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:30:04Z","timestamp":1788471004879,"version":"build-2803163510"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"Importance<\/jats:title>Hyperbaric oxygen therapy (HBOT) is proposed as treatment for late local toxic effects after breast irradiation. Strong evidence of effectiveness is lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess effectiveness of HBOT for late local toxic effects in women who received adjuvant radiotherapy for breast cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This was a hospital-based, pragmatic, 2-arm, randomized clinical trial nested within the prospective UMBRELLA cohort following the trials within cohorts design in the Netherlands. Participants included 189 women with patient-reported moderate or severe breast, chest wall, and\/or shoulder pain in combination with mild, moderate, or severe edema, fibrosis, or movement restriction 12 months or longer after breast irradiation. Data analysis was performed from May to September 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Receipt of 30 to 40 HBOT sessions over a period of 6 to 8 consecutive weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Breast, chest wall, and\/or shoulder pain 6 months postrandomization measured by the European Organization for Research and Treatment of Cancer QLQ-BR23 questionnaire. Secondary end points were patient-reported fibrosis, edema, movement restriction, and overall quality of life. Data were analyzed according to intention-to-treat (ITT) and complier average causal effect (CACE) principles.<\/jats:p><\/jats:sec>Results<\/jats:title>Between November 2019 and August 2022, 125 women (median [range] age at randomization, 56 [37-85] years) with late local toxic effects were offered to undergo HBOT (intervention arm), and 61 women (median [range] age at randomization, 60 [36-80] years) were randomized to the control arm. Of those offered HBOT, 31 (25%) accepted and completed treatment. The most common reason for not accepting HBOT was high treatment intensity. In ITT, moderate or severe pain at follow-up was reported by 58 of 115 women (50%) in the intervention arm and 32 of 52 women (62%) in the control arm (odds ratio [OR], 0.63; 95% CI, 0.32-1.23; P<\/jats:italic>\u2009=\u2009.18). In CACE, the proportion of women reporting moderate or severe pain at follow-up was 32% (10 of 31) among those completing HBOT and 75% (9.7 of 12.9) among control participants expected to complete HBOT if offered (adjusted OR, 0.34; 95% CI, 0.15-0.80; P<\/jats:italic>\u2009=\u2009.01). In ITT, moderate or severe fibrosis was reported by 35 of 107 (33%) in the intervention arm and 25 of 49 (51%) in the control arm (OR, 0.36; 95% CI, 0.15-0.81; P<\/jats:italic>\u2009=\u2009.02). There were no significant differences in breast edema, movement restriction, and quality of life between groups in ITT and CACE.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, offering HBOT to women with late local toxic effects was not effective for reducing pain, but was effective for reducing fibrosis. In the subgroup of women who completed HBOT, a significant reduction in pain and fibrosis was observed. A smaller than anticipated proportion of women with late local toxic effects was prepared to undergo HBOT.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04193722<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.6776","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:07:22Z","timestamp":1707408442000},"page":"464","source":"Crossref","is-referenced-by-count":18,"title":["Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Dieuwke R.","family":"Mink van der Molen","sequence":"first","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Centre Utrecht, Cancer Centre, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilot C. T.","family":"Batenburg","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Centre Utrecht, Cancer Centre, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje","family":"Maarse","sequence":"additional","affiliation":[{"name":"Department of Plastic, Reconstructive and Hand Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree H. J. G.","family":"van den Bongard","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Doeksen","sequence":"additional","affiliation":[{"name":"Department of Surgery, St Antonius Hospital, Nieuwegein, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjoleine Y.","family":"de Lange","sequence":"additional","affiliation":[{"name":"Alexander Monro Hospital, Bilthoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C.","family":"van der Pol","sequence":"additional","affiliation":[{"name":"Department of Surgery, Alrijne Hospital, Leiderdorp, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hospital Group Twente, Hengelo, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine A.","family":"Lansdorp","sequence":"additional","affiliation":[{"name":"Da Vinci Clinic, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacco","family":"van der Laan","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Centre Utrecht, Cancer Centre, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"van de Ven","sequence":"additional","affiliation":[{"name":"The Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van der Leij","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Centre Utrecht, Cancer Centre, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Verkooijen","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Centre Utrecht, Cancer Centre, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi230087r1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/tbj.v25.5","article-title":"An actualised population-based study on the use of radiotherapy in breast cancer patients in the Netherlands.","volume":"25","author":"Schreuder","year":"2019","journal-title":"Breast J"},{"issue":"2","key":"coi230087r2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.radonc.2011.05.012","article-title":"An increased utilisation rate and better compliance to guidelines for primary radiotherapy for breast cancer from 1997 till 2008: a population-based study in the Netherlands.","volume":"100","author":"Struikmans","year":"2011","journal-title":"Radiother Oncol"},{"issue":"9804","key":"coi230087r3","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"issue":"9935","key":"coi230087r4","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"issue":"9618","key":"coi230087r5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.","volume":"371","author":"Bentzen","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"coi230087r6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.ijrobp.2022.11.008","article-title":"Patient-reported symptoms of late toxicity in patients with breast cancer treated with hypofractionated radiation therapy and the association with quality of life.","volume":"115","author":"Batenburg","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi230087r7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.breast.2022.12.009","article-title":"Hyperbaric oxygen therapy for local late radiation toxicity in breast cancer patients: a systematic review.","volume":"67","author":"Meier","year":"2023","journal-title":"Breast"},{"issue":"5","key":"coi230087r8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0002-9610(05)81019-0","article-title":"Relationship of oxygen dose to angiogenesis induction in irradiated tissue.","volume":"160","author":"Marx","year":"1990","journal-title":"Am J Surg"},{"key":"coi230087r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102352","article-title":"Hyperbaric oxygen therapy for healthy aging: from mechanisms to therapeutics.","volume":"53","author":"Fu","year":"2022","journal-title":"Redox Biol"},{"issue":"1","key":"coi230087r10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13014-016-0700-0","article-title":"Hyperbaric oxygen therapy for late radiation-induced tissue toxicity: prospectively patient-reported outcome measures in breast cancer patients.","volume":"11","author":"Teguh","year":"2016","journal-title":"Radiat Oncol"},{"issue":"3","key":"coi230087r11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ijrobp.2008.11.056","article-title":"Early hyperbaric oxygen therapy for reducing radiotherapy side effects: early results of a randomized trial in oropharyngeal and nasopharyngeal cancer.","volume":"75","author":"Teguh","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7753","key":"coi230087r12","doi-asserted-by":"publisher","first-page":"c1066","DOI":"10.1136\/bmj.c1066","article-title":"Rethinking pragmatic randomised controlled trials: introducing the \u201ccohort multiple randomised controlled trial\u201d design.","volume":"340","author":"Relton","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"coi230087r13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10549-017-4242-4","article-title":"The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results.","volume":"164","author":"Young-Afat","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"coi230087r14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s13063-020-04869-z","article-title":"Assessing the effect of hyperbaric oxygen therapy in breast cancer patients with late radiation toxicity (HONEY trial): a trial protocol using a trial within a cohort design.","volume":"21","author":"Batenburg","year":"2020","journal-title":"Trials"},{"key":"coi230087r15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jclinepi.2022.04.015","article-title":"Most patients reported positively or neutrally of having served as controls in the trials within cohorts design.","volume":"148","author":"Verweij","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"coi230087r16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinepi.2019.12.015","article-title":"The trials within cohorts design facilitated efficient patient enrollment and generalizability in oncology setting.","volume":"120","author":"Couwenberg","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"7748","key":"coi230087r17","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"coi230087r18","doi-asserted-by":"publisher","first-page":"n857","DOI":"10.1136\/bmj.n857","article-title":"CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration.","volume":"373","author":"Kwakkenbos","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"coi230087r24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"coi230087r25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"coi230087r26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.28920\/dhm","article-title":"The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer: a case-series of 67 patients.","volume":"50","author":"Spruijt","year":"2020","journal-title":"Diving Hyperb Med"},{"issue":"1","key":"coi230087r27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12874-016-0208-1","article-title":"Cohort Multiple Randomised Controlled Trials (cmRCT) design: efficient but biased? a simulation study to evaluate the feasibility of the Cluster cmRCT design.","volume":"16","author":"Pate","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"434","key":"coi230087r28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/01621459.1996.10476902","article-title":"Identification of causal effects using instrumental variables.","volume":"91","author":"Angrist","year":"1996","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"coi230087r29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1191\/0962280205sm403oa","article-title":"Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods.","volume":"14","author":"Dunn","year":"2005","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"coi230087r30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s11121-008-0104-y","article-title":"Estimating intervention effects of prevention programs: accounting for noncompliance.","volume":"9","author":"Stuart","year":"2008","journal-title":"Prev Sci"},{"issue":"2","key":"coi230087r31","article-title":"Using instrumental variable estimation to evaluate randomized experiments with imperfect compliance.","volume":"23","author":"Huang","year":"2018","journal-title":"Pract Assess, Res Eval"},{"issue":"9","key":"coi230087r32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V","article-title":"Adjusting for non-compliance and contamination in randomized clinical trials.","volume":"16","author":"Cuzick","year":"1997","journal-title":"Stat Med"},{"issue":"1","key":"coi230087r33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12874-017-0295-7","article-title":"Evaluation of biases present in the cohort multiple randomised controlled trial design: a simulation study.","volume":"17","author":"Candlish","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"coi230087r34","first-page":"96","article-title":"The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials?","volume":"46","author":"van der Velden","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1","key":"coi230087r35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12885-017-3144-5","article-title":"Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.","volume":"17","author":"Charaghvandi","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"coi230087r36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10549-021-06332-2","article-title":"The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients.","volume":"189","author":"Batenburg","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"coi230087r37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jpain.2010.12.005","article-title":"Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention.","volume":"12","author":"Andersen","year":"2011","journal-title":"J Pain"},{"issue":"1","key":"coi230087r38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13643-021-01790-7","article-title":"Enrollment, retention, and strategies for including disadvantaged populations in randomized controlled trials: a systematic review protocol.","volume":"10","author":"LaPlante","year":"2021","journal-title":"Syst Rev"},{"issue":"4","key":"coi230087r39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2020.06.013","article-title":"Efficacy of dose-escalated chemoradiation on complete tumor response in patients with locally advanced rectal cancer (RECTAL-BOOST): a phase 2 randomized controlled trial.","volume":"108","author":"Couwenberg","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"coi230087r40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/bjs\/znac249","article-title":"SPONGE-assisted versus Trendelenburg position surgery in laparoscopic sigmoid and rectal cancer surgery (SPONGE trial): randomized clinical trial.","volume":"109","author":"Fahim","year":"2022","journal-title":"Br J Surg"},{"issue":"1","key":"coi230087r41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-021-06363-9","article-title":"Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial.","volume":"190","author":"Gal","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"coi230087r42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1740774518776952","article-title":"Double-blind trials in hyperbaric medicine: a narrative review on past experiences and considerations in designing sham hyperbaric treatment.","volume":"15","author":"Lansdorp","year":"2018","journal-title":"Clin Trials"},{"key":"coi230087r20","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-47140-2","volume-title":"Textbook of Hyperbaric Medicine","author":"Jain","year":"2017","edition":"6th ed"},{"key":"coi230087r19","unstructured":"Netherlands Cancer Registry. Accessed December 22, 2020. https:\/\/nkr-cijfers.iknl.nl\/viewer"},{"key":"coi230087r21","unstructured":"Latham? E. Hyperbaric oxygen therapy: overview, hyperbaric physics and physiology, contraindications. Accessed April 25, 2023. https:\/\/emedicine.medscape.com\/article\/1464149-overview#a3"},{"key":"coi230087r22","unstructured":"Da Vinci Clinic. Accessed January 4, 2024. https:\/\/davincikliniek.nl\/"},{"key":"coi230087r23","unstructured":"US Department of Health and Human Services National Cancer Institute. Common terminology criteria of adverse events (CTCAE) version 4.3. Accessed January 4, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2814857\/jamaoncology_mink_van_der_molen_2024_oi_230087_1712704293.15703.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:03:16Z","timestamp":1713452596000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2814857"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.6776","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}